News & Events
February 20, 2023
3rd PSTC Japan Safety Biomarker WorkshopWith the cooperation and support of NIHS, JSSX, JSCPT, JSOT and JPMA, C-Path’s Predictive Safety Testing Consortium (PSTC) is delighted to announce the 3rd PSTC Japan Safety Biomarker Workshop to be held February 20, 2023 in Fujisawa, Japan. The utilization of biomarkers in guiding drug development decisions through clinical trials and post marketing studies is increasing. This......
December 15, 2022
Register Now: Critical Path to Women Leading in ScienceDate: Dec 15, 2022 | 2:30 PM Eastern Time (US and Canada) Please join C-Path for a 90-minute roundtable discussing the Critical Path Institute’s programs and consortia, highlighted by various women leaders at this public-private partnership. The team will discuss how C-Path contributes to transforming and accelerating the medical product development process, as well......
December 14, 2022
Register Now | Shared Stewardship in Collaborative Curation of Rare Disease Datasets
In this talk, we will discuss some of the best practices and collaborative approaches utilized by NORD and C-Path. From collection through curation, we will demonstrate the importance of data stewardship and its consistency throughout.
December 11, 2022 - December 14, 2022
15th Annual Conference on the Science of Dissemination and Implementation in HealthDec 11-14, Academy Health, Washington, DC Summary: Through a combination of plenaries, workshops, breakout, and poster sessions, the 15th Annual Conference on the Science of Dissemination and Implementation in Health, co-hosted by the National Institutes of Health (NIH) and AcademyHealth, supports the collective understanding of the research agenda, puts forth new findings, and identifies research......
December 1, 2022
C-Path and Ultragenyx Announce Data Sharing Agreement to Support Rare Disease Treatment and Novel Therapies
C-Path and Ultragenyx Pharmaceutical, Inc., (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for serious rare and ultra-rare genetic diseases, today announced a data sharing agreement to incorporate rare disease patient data into C-Path’s Rare Disease Cures Accelerator-Data and Analytics Platform (RDCA-DAP®).